SynAct Pharma
A clinical-stage biotech developing medicines designed to resolve inflammation.
SYNACT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008241491 (+1 more)
- LEI:
- 549300RRYIEFEQ72N546
- Country:
- Sweden
- Address:
- Scheelevägen 2, 223 63 Lund
- Website:
- https://synactpharma.com/en/
- Sector:
- Manufacturing
Description
SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-11 15:00 |
Valberedning utsedd inför årsstämman 2026 i SynAct Pharma AB
|
Swedish | 55.0 KB | ||
| 2025-12-11 15:00 |
Nomination committee appointed ahead of AGM 2026 in SynAct Pharma AB
|
English | 55.0 KB | ||
| 2025-11-27 11:15 |
Report from the Extraordinary General Meeting of SynAct Pharma AB
|
English | 58.8 KB | ||
| 2025-11-27 11:15 |
Kommuniké från extra bolagsstämma i SynAct Pharma AB
|
Swedish | 57.4 KB | ||
| 2025-10-30 07:30 | Swedish | 2.4 MB | |||
| 2025-10-30 07:30 | English | 2.4 MB | |||
| 2025-10-29 18:30 |
KALLELSE TILL EXTRA BOLAGSSTÄMMA I SYNACT PHARMA AB (PUBL)
|
Swedish | 84.6 KB | ||
| 2025-10-29 18:30 |
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SYNACT PHARMA AB
|
English | 84.7 KB | ||
| 2025-09-29 07:45 |
Förslag till beslut om bemyndigande för styrelsen att besluta om förvärv och öv…
|
Swedish | 55.9 KB | ||
| 2025-09-29 07:45 |
Proposal for a resolution on authorization for the Board of Directors to resolv…
|
English | 56.5 KB | ||
| 2025-09-16 08:45 |
SynAct Pharma’s CFO Björn Westberg leaves for new leading position
|
English | 53.7 KB | ||
| 2025-09-16 08:45 |
SynAct Pharmas CFO Björn Westberg slutar för ny ledande befattning
|
Swedish | 53.4 KB | ||
| 2025-08-29 18:00 |
Förändring av antalet aktier och röster i SynAct Pharma AB
|
Swedish | 58.9 KB | ||
| 2025-08-29 18:00 |
Change in number of shares and votes in SynAct Pharma AB
|
English | 58.9 KB | ||
| 2025-08-20 07:30 | Swedish | 6.6 MB |
Automate Your Workflow. Get a real-time feed of all SynAct Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SynAct Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SynAct Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-30 | Anders Kronborg | Other | Buy | 28,902 | 250,002.30 SEK |
| 2024-06-01 | Björn Westberg | Other | Other | 516,205 | N/A |
| 2024-04-30 | Jeppe Øvlesen | Other | Other | 58,139 | 499,995.40 SEK |
| 2024-04-30 | Anders Kronborg | Other | Other | 34,883 | 299,993.80 SEK |
| 2024-03-21 | Jeppe Øvlesen | Other | Other | 245,870 | 1,696,503.00 SEK |
| 2023-11-09 | Thomas Jonassen | Other | Other | 3,531,644 | 22,072,775.00 SEK |
| 2023-11-09 | Thomas Jonass | Other | Other | 2,161,225 | 13,507,656.25 SEK |
| 2023-01-16 | Jeppe Øvlesen | Other | Other | 1,161,777 | 72,727,240.20 SEK |
| 2023-01-16 | James Knight | Other | Other | 77,452 | 4,848,495.20 SEK |
| 2023-01-16 | Thomas Boesen | Other | Other | 32,917 | 2,060,604.20 SEK |
Peer Companies
